Edgewise Therapeutics (EWTX), on Thursday, announced that it will host a live webcast on Wednesday, April 2, 2025, at 8:30 AM ET to discuss the top-line results from its Phase 2 CIRRUS-HCM 28-day trial of EDG-7500 in patients with hypertrophic cardiomyopathy or HCM.
HCM, the leading cause of sudden cardiac death in young people, is a hereditary heart condition characterized by the thickening of the heart muscle, making it harder for the heart to pump blood effectively. Some of the common symptoms of HCM include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com